Randomized phase III study of rituximab with intensified CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] chemotherapy versus rituximab with high-dose sequential therapy and autologous stem cell transplantation in adult patients (18-65 years) with stage II-IV high-intermediate or high risk DLBCL [diffuse large B-cell lymphoma]
Latest Information Update: 03 Sep 2021
At a glance
- Drugs Rituximab (Primary) ; Antineoplastics; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms HOVON 63 NHL
- 29 Aug 2021 Status changed to recruiting.
- 01 Jan 2009 Status changed from active, no longer recruiting to completed, according to the current controlled trials (ISRCTN) record.
- 08 Feb 2006 New trial record.